Best GLP-1 Medications for Weight Loss: A Patient’s Comparison Guide

The most effective GLP-1-based medications for weight loss are tirzepatide and semaglutide. Head-to-head data favor tirzepatide for average total body-weight reduction, while semaglutide also has strong evidence. Liraglutide tends to produce less weight loss. The right choice depends on eligibility, side effects, cost, coverage, and clinician guidance [1,2,3,8].

What is a GLP-1, and how does it cause weight loss?

GLP-1 medications work by copying or enhancing signals from hormones involved in appetite and blood sugar control. GLP-1 receptor agonists act on receptors in the brain and gut that help regulate hunger, fullness, insulin release, glucagon release, and gastric emptying, which means food may leave the stomach more slowly [1,4].

For weight loss, the main effect is lower appetite and earlier fullness. In clinical trials, people taking these medicines also received lifestyle counseling, and results varied from person to person [6,7,8]. Common side effects include nausea, vomiting, diarrhea, constipation, and stomach pain; serious risks and contraindications depend on the specific medication label [1,2,3].

Which GLP-1 medications are FDA-approved for weight loss?

The main FDA-approved GLP-1-based prescription options for chronic weight management are semaglutide, tirzepatide, and liraglutide. Their labels define who may use them, dose titration schedules studied for approval, contraindications, and safety warnings [1,2,3].

Semaglutide (Wegovy)

Wegovy is semaglutide, a GLP-1 receptor agonist; semaglutide may also be available as a compounded formulation through licensed 503A pharmacies when prescribed for an individual patient. Wegovy is FDA-approved for chronic weight management in adults with obesity or adults with overweight and at least one weight-related condition, and for certain pediatric patients aged 12 years and older with obesity [1].

The FDA-approved Wegovy label starts semaglutide at 0.25 mg once weekly for 4 weeks and titrates to maintenance doses that may include 1.7 mg or 2.4 mg once weekly, depending on the label and clinical context [1]. In the STEP 1 trial, semaglutide 2.4 mg once weekly plus lifestyle intervention produced a mean body-weight change of -14.9% at 68 weeks, compared with -2.4% with placebo; individual results vary [6]. Semaglutide can cause nausea, diarrhea, vomiting, constipation, abdominal pain, and has boxed-warning language about thyroid C-cell tumors in rodents; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1].

Tirzepatide (Zepbound) — a dual GIP/GLP-1

Zepbound is tirzepatide, a dual GIP/GLP-1 receptor agonist; tirzepatide may also be available as compounded tirzepatide through licensed 503A pharmacies when prescribed for a specific patient. Zepbound is FDA-approved for chronic weight management in adults with obesity or adults with overweight and at least one weight-related condition [2].

The FDA-approved Zepbound label starts tirzepatide at 2.5 mg once weekly for 4 weeks, with stepwise increases to labeled maintenance doses of 5 mg, 10 mg, or 15 mg once weekly [2]. In SURMOUNT-1, tirzepatide 5 mg, 10 mg, and 15 mg once weekly led to mean weight changes of -15.0%, -19.5%, and -20.9% at 72 weeks, compared with -3.1% with placebo; individual results vary [7]. Side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia, and the label includes a boxed warning about thyroid C-cell tumors in rodents plus contraindications for medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 [2].

Liraglutide (Saxenda)

Saxenda is liraglutide, a GLP-1 receptor agonist that is FDA-approved for chronic weight management in adults with obesity, adults with overweight and a weight-related condition, and certain pediatric patients aged 12 years and older with obesity [3]. Unlike weekly semaglutide and tirzepatide, liraglutide is given once daily under its FDA-approved label [3].

The FDA-approved Saxenda label uses a titration schedule that begins at 0.6 mg once daily and increases weekly to 3 mg once daily [3]. In the SCALE Obesity and Prediabetes trial, liraglutide 3 mg daily plus lifestyle intervention led to greater average weight loss than placebo at 56 weeks; individual results vary [12]. Side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, and the label includes a boxed warning about thyroid C-cell tumors in rodents with the same medullary thyroid carcinoma and MEN2 contraindications [3].

Off-label use of Ozempic and Mounjaro

Ozempic is semaglutide and Mounjaro is tirzepatide, but both are FDA-approved for type 2 diabetes, not chronic weight management [4,5]. Using Ozempic or Mounjaro mainly for weight loss is off-label; it may be discussed in clinical practice, but it should be reviewed with a licensed clinician who can consider the approved alternatives, safety history, and coverage limits [4,5,11].

Which GLP-1 causes the most weight loss? Comparing head-to-head data

Tirzepatide has shown the largest average weight-loss effect among GLP-1-based options in available head-to-head and placebo-controlled obesity trials, including a 72-week head-to-head comparison with semaglutide. That does not mean it is best for every person. Side effects, contraindications, medication access, and insurance coverage can change the decision [1,2,8].

A useful way to compare these medicines is to ask two questions: which medicine has the strongest evidence for average weight loss, and which one is safest and most practical for this person. A clinician should review medical history, pregnancy plans, gallbladder disease, pancreatitis history, kidney problems, current medicines, and past side effects before choosing [1,2,3,11].

What about compounded semaglutide and tirzepatide?

Compounded semaglutide and compounded tirzepatide are prescription medications made for an individual patient by a licensed compounding pharmacy, often a 503A pharmacy. They are not FDA-approved products, which means FDA has not reviewed them for safety, effectiveness, or quality the way it reviews Wegovy or Zepbound [10].

Compounding may be considered when a licensed clinician decides it is appropriate for a patient, but it should not be treated as the same thing as using an FDA-approved brand product. The FDA has warned patients and clinicians about dosing errors and concerns related to some compounded semaglutide products, including products made with semaglutide salts rather than the base form used in approved drugs [10].

What are the side effects and risks of GLP-1s?

GLP-1 side effects are usually gastrointestinal. The common ones include nausea, vomiting, diarrhea, constipation, stomach pain, indigestion, and decreased appetite. These effects are listed across the FDA labels for semaglutide, tirzepatide, and liraglutide, though rates vary by drug and dose studied [1,2,3].

• Boxed warning: Wegovy, Zepbound, and Saxenda include warnings about thyroid C-cell tumors seen in rodents; they are contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2 [1,2,3].
• Pancreatitis: GLP-1-based labels warn clinicians to stop the medication if pancreatitis is suspected and to avoid restarting if confirmed [1,2,3].
• Gallbladder problems: gallstones and gallbladder inflammation have been reported with GLP-1-based weight-loss medicines [1,2,3].
• Kidney injury risk: dehydration from severe nausea, vomiting, or diarrhea can worsen kidney function in some people [1,2,3].
• Low blood sugar: risk is higher when GLP-1-based medicines are used with insulin or insulin secretagogues such as sulfonylureas [1,2,4,5].
• Pregnancy: FDA labels advise stopping these medicines when pregnancy is recognized or before planned pregnancy according to label-specific guidance, because weight loss is not recommended during pregnancy [1,2,3].

The benefits and risks should be discussed together. A medication that produces more average weight loss may also be harder to tolerate for some people, and severe side effects can make continuing unsafe or unrealistic [1,2,8].

Who is a candidate for a GLP-1 for weight loss?

FDA-approved weight-loss GLP-1 options are generally labeled for adults with obesity, or adults with overweight plus at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. The exact eligibility language is in each product label, and adolescent eligibility differs by medication [1,2,3].

Clinical guidelines also advise that anti-obesity medications can be considered as part of long-term care for people who meet body-mass-index and health-risk criteria, alongside nutrition, physical activity, sleep, and behavior support [11]. A clinician still needs to check contraindications, other medicines, pregnancy plans, eating-disorder history, gastrointestinal disease, kidney or gallbladder concerns, and personal goals [1,2,3,11].

How much do GLP-1 medications cost, and how do you get one?

GLP-1 cost depends on the medication, insurance coverage, pharmacy, dose form, and whether the prescription is for an FDA-approved product or a compounded medication. Brand-name Wegovy, Zepbound, and Saxenda may require prior authorization, and coverage can differ between obesity treatment and diabetes treatment [1,2,3].

To get a GLP-1 for weight loss, the usual path is a clinical visit, eligibility review, safety screening, prescription if appropriate, and ongoing follow-up. Licensed telehealth providers, primary-care clinicians, endocrinologists, and obesity-medicine clinicians can all evaluate patients; Chia is one telehealth option that offers clinician-reviewed access to compounded GLP-1 treatment through licensed 503A pharmacy partners when appropriate.

A 503A compounding pharmacy prepares a medication for an individual patient based on a valid prescription. Compounded GLP-1s are not FDA-approved products, so patients should ask how the pharmacy verifies potency, sterility for injectable products, ingredient source, and instructions to reduce dosing errors [10].

How long do you stay on a GLP-1, and what happens when you stop?

GLP-1 treatment for obesity is often managed as long-term care, not a short reset. Obesity is a chronic disease, and guidelines describe anti-obesity medications as part of ongoing care for people who benefit and can use them safely [11].

Stopping can lead to weight regain for many people. In an extension of the STEP 1 trial, participants regained about two-thirds of the weight they had lost during the year after semaglutide 2.4 mg and lifestyle intervention were withdrawn; individual results vary [9]. That finding should be balanced with side effects, cost, pregnancy plans, access, and whether the medication remains safe and useful over time [1,9,11].

If a medication is stopped, a clinician may help plan nutrition, activity, sleep, behavior support, and follow-up weight and metabolic monitoring. Do not stop or restart a prescription medicine without guidance from the prescriber, especially if you also take diabetes or blood-pressure medicines [1,2,4,5].

Frequently asked questions

Keep reading

GLP-1 Weight Loss

How to Get a GLP-1 Prescription Online: What to Expect, Who Qualifies, and What It Costs

GLP-1 Weight Loss

How to Get Weight-Loss Injections Online: A Step-by-Step Guide

GLP-1 Weight Loss

GLP-1 for Weight Loss Online: Prescription Options, Costs, and Safety